Albany Molecular Research (AMRI) Tops Q3 EPS by 2c, Lifts Guidance
Tweet
Share
E-mailGet Alerts AMRI Hot Sheet
Price: $21.74 --0%
Financial Fact:
Income tax expense (benefit): -5.5M
Today's EPS Names:
NLY, CP, RUSHA, More
Financial Fact:
Income tax expense (benefit): -5.5M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Albany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $55.8 million versus the consensus estimate of $50.8 million.
Albany Molecular Research sees FY2012 EPS of $0.16-0.20, versus prior guidance of $0.10-0.16 and the consensus of $0.12. Albany Molecular Research sees FY2012 revenue of $50-56 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Albany Molecular Research sees FY2012 EPS of $0.16-0.20, versus prior guidance of $0.10-0.16 and the consensus of $0.12. Albany Molecular Research sees FY2012 revenue of $50-56 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Alamos Gold (AGI) Misses Q1 EPS by 1c
- Northrim BanCorp (NRIM) Tops Q1 EPS by 54c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
